New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies

Michael Raymond Binder

doi:doi:10.11648/j.ajcem.20221001.15

| Peer-Reviewed

New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies

Michael Raymond Binder

Published in American Journal of Clinical and Experimental Medicine (Volume 10, Issue 1)

Received: 31 January 2022 Accepted: 18 February 2022 Published: 28 February 2022

Views: Downloads:

Download PDF

Share This Article

Twitter
Linked In
Facebook

Abstract

Although psychotherapy and pharmacotherapy continue to be first-line treatments for a wide range of mental and emotional disorders, a high percentage of patients are ultimately considered to be treatment-resistant. For more than half a century, electroconvulsive therapy had been the gold-standard for such patients. However, in recent years a variety of alternative treatment modalities have been developed for these patients, including deep brain stimulation, vagus nerve stimulation, repetitive transcranial magnetic stimulation, stellate ganglion block, and sub-anesthetic doses of the dissociative drug ketamine. Although these alternative treatments have offered new hope for many patients, there is a great deal of individual variability in their degree of effectiveness, and their mechanisms of action, like standard treatments, remain unclear. However, an emerging hypothesis contends that psychiatric symptoms are driven by pathological hyperactivity in symptom-related circuits in the brain. According to the Multi-Circuit Neuronal Hyperexcitability (MCNH) Hypothesis of Psychiatric Disorders, persistent firing in anxiety circuits causes persistent feelings of anxiety; persistent firing in depressive circuits causes persistent feelings of depression; persistent firing in cognitive circuits causes ruminative and obsessive thoughts; etc... The aim of this review is twofold: the first is to discuss the new hypothesis in relation to the aforementioned treatment strategies; and the second is to tease out the shared neurophysiological effects of past and present treatment strategies to determine whether they support or refute the new hypothesis. Clarifying the cause of mental illness is of critical importance to curbing the escalating mental health crisis, as new medications and emergent treatment strategies are failing to keep up with the steady rise in domestic disputes, suicides, homicides, and mass shootings that are driving the disintegration of individuals, families, and communities.

Published in	American Journal of Clinical and Experimental Medicine (Volume 10, Issue 1)
DOI	10.11648/j.ajcem.20221001.15
Page(s)	38-48
Creative Commons	This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited.
Copyright	Copyright © The Author(s), 2022. Published by Science Publishing Group

Keywords

Pathophysiology of Psychiatric Disorders, Neuronal Excitability Spectrum, Anticonvulsants, Neuroregulators, ECT, VNS, rTMS, Ketamine

References

[1]	Cuijpers P, Karyotaki E, Ciharova M, et al. The effects of psychotherapies for depression on response, remission, reliable change, and deterioration: A meta-analysis. Acta Psychiatr Scand 2021; 144 (3): 288-299.
[2]	Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry 2006; 163 (11): 1905-1917.
[3]	Souery D, Oswald P, Massat I, et al; Group for the Study of Resistant Depression. Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study. J Clin Psychiatry 2007; 68 (7): 1062-1070.
[4]	Fosse R, Read J. Electroconvulsive treatment: hypotheses about mechanisms of action. Front Psychiatry 2013; 4 (94).
[5]	Fitzgerald PB, Daskalakis ZJ. The effects of repetitive transcranial magnetic stimulation in the treatment of depression. Expert Review of Medical Devices 2014; 8 (1): 85-95.
[6]	Wu Y, Mo J, Sui L, et al. Deep brain stimulation in treatment-resistant depression: A systematic review and meta-analysis on efficacy and safety. Front Neurosci 2021.
[7]	Tisi G, Franzini A, Messina G, Savino M, Gambini O. Vagus nerve stimulation therapy in treatment-resistant depression: A series report. Psychiatry and Clinical Neurosciences 2014; 68 (8): 606-611.
[8]	Li Y, Loshak H. Stellate ganglion block for the treatment of post-traumatic stress disorder, depression, and anxiety [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2021.
[9]	Mandal S, Sinha VK, Goyal N. Efficacy of ketamine therapy in the treatment of depression. Indian J Psychiatry 2019; 61 (5): 480-485.
[10]	Binder MR. The multi-circuit neuronal hyperexcitability hypothesis of psychiatric disorders. AJCEM 2019; 7 (1): 12-30.
[11]	Binder MR: The neuronal excitability spectrum: A new paradigm in the diagnosis, treatment, and prevention of mental illness and its relation to chronic disease. AJCEM; 2021; 9 (6); 187-203.
[12]	Binder MR. A pathophysiolgically-based approach to the treatment and prevention of mental illness and its related disorders. AJCEM 2021; 9 (6): 223-232.
[13]	Binder MR. New hypothesis unifies previous theories of psychopathology and identifies core biological abnormality in psychiatric disorders. AJCEM 2022; In Press.
[14]	Cerf M, Thiruvengadam N, Mormann F, et al. On-line, voluntary control of human temporal lobe neurons. Nature 2010; 467: 1104-1108.
[15]	Penfield W. Epilepsy and surgical therapy. Archives of Neurology and Psychiatry 1936; 36 (3): 449-484.
[16]	Al-Shargie F, Kiguchi M, Badruddin N, et al. Mental stress assessment using simultaneous measurement of EEG and fNIRS. Biomedical Optics Express 2016; 7 (10): 3882-3898.
[17]	Mazarati A, Shin D, Auvin S, Caplan R, Sankar R. Kindling epileptogenesis in immature rats leads to persistent depressive behavior. Epilepsy Behav 2007; 10: 377–383.
[18]	van der Gaag M. A neuropsychiatric model of biological and psychological processes in the remission of delusions and auditory hallucinations. Schizophr Bull 2006; 32 (Suppl 1): S113-S122.
[19]	Hare BD, Duman RS. Prefrontal cortex circuits in depression and anxiety: contribution of discrete neuronal populations and target regions. Mol Psychiatry 2020; 25 (11): 2742-2758.
[20]	Tik M, Hoffmann A, Sladky R, et al. Towards understanding rTMS mechanism of action: Stimulation of the DLPFC causes network-specific increase in functional connectivity. NeuroImage 2017; 162: 289-296.
[21]	Ferreira MAR, O’Donovan MC, Sklar P. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet 2008; 40 (9): 1056-1058.
[22]	Yuan A, Yi Z, Wang Q, et al. ANK3 as a risk gene for schizophrenia: new data in Han Chinese and meta analysis. Am J Med Genet B Neuropsychiatr Genet 2012; 159B (8): 997-1005.
[23]	Green EK, Grozeva D, Jones I, et al. Wellcome Trust Case Control Consortium, Holmans, PA, Owen, MJ, O'Donovan, MC, Craddock N. The bipolar disorder risk allele at CACNA1C also confers risk of recurrent major depression and of schizophrenia. Mol Psychiatry 2010; 15 (10): 1016-1022.
[24]	Binder MR. Neuronal hyperexcitability: significance, cause, and diversity of clinical expression. AJCEM 2021; 9 (5): 163-173.
[25]	Binder MR. FLASH Syndrome: tapping into the root of chronic illness. AJCEM 2020; 8 (6): 101-109.
[26]	Binder MR. Neuronal hyperexcitability: The elusive but modifiable instigator of disease. AJCEM 2022; 10 (1): 1-7.
[27]	Binder MR. Electrophysiology of seizure disorders may hold key to the pathophysiology of psychiatric disorders. AJCEM 2019; 7 (5): 103-110.
[28]	Binder MR. Anticonvulsants: The psychotropic and medically protective drugs of the future. AJCEM 2021; 9 (5): 180-188.
[29]	Ciccarone D. Stimulant abuse: pharmacology, cocaine, methamphetamine, treatment, attempts at pharmacotherapy. Prim Care 2011; 38 (1): 41-58.
[30]	Hillhouse TM, Porter JH. A brief history of the development of antidepressant drugs: from monoamines to glutamate. Exp Clin Psychopharmacol 2015; 23 (1): 1-21.
[31]	Ramachandraih CT, Subramanyam N, Bar KJ, Baker G, Yeragani VK. Antidepressants: from MAOIs to SSRIs and more. Indian Journal of Psychiatry 2011; 53 (2): 180-182.
[32]	Zarate C Niciu M. Ketamine for depression: evidence, challenges and promise. World Psychiatry 2015; 14 (3): 348–350.
[33]	Kanes S, Colquhoun H, Gunduz-Bruce H, et al.: Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial. Lancet 2017; 390: 480–489.
[34]	Meltzer-Brody S, Colquhoun H, Riesenberg R, et al. Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet 2018; 392: 1058–1070.
[35]	Frey R, Schreinzer D, Heiden A, Kasper S. Einsatz der Elektrokrampftherapie in der Psychiatrie [Use of electroconvulsive therapy in psychiatry]. Nervenarzt 2001; 72 (9): 661-676.
[36]	Baldinger P, Lotan A, Frey R, Kasper S, Lerer B, Lanzenberger R. Neurotransmitters and electroconvulsive therapy. J ECT 2014; 30 (2): 116-121.
[37]	Guloksuz S, Rutten BP, Arts B, van Os J, Kenis G. The immune system and electroconvulsive therapy for depression. J ECT. 2014; 30 (2): 132-137.
[38]	de Jong JO, Arts B, Boks MP, Sienaert P, van den Hove DL, et al. Epigenetic effects of electroconvulsive seizures. J ECT 2014; 30 (2): 152-159.
[39]	Bouckaert F, Sienaert P, Obbels J, Dols A, Vandenbulcke M, et al. ECT: its brain enabling effects: a review of electroconvulsive therapy-induced structural brain plasticity. J ECT 2014; 30 (2): 143-151.
[40]	Lado FA, Moshé SL. How do seizures stop? Epilepsia 2008; 49 (10): 1651-1654.
[41]	Sabbatini, RME. The history of shock therapy in psychiatry. http://www.cerebromente.org.br/n04/historia/shock_i.htm. (Accessed 8/23/18).
[42]	Sackeim HA, Haskett RF, Mulsant BH, Thase ME, Mann JJ, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA 2001; 285 (10): 1299-1307.
[43]	Goddard GV. Development of epileptic seizures through brain stimulation at low intensity. Nature 1967; 214: 1020-1021.
[44]	Rose GM, Diamond DM, Pang K, Dunwiddie TV. Primed burst potentiation: lasting synaptic plasticity invoked by physiologically patterned stimulation. In: Haas HL, Buzsàki G. (eds) Synaptic plasticity in the hippocampus. Springer, Berlin, Heidelberg, 1988.
[45]	Binder MR. Introducing the term “Neuroregulator” in psychiatry. AJCEM 2019; 7 (3): 66-70.
[46]	García-Medina NE, Miranda MI. Nucleus of the solitary tract chemical stimulation induces extracellular norepinephrine release in the lateral and basolateral amygdala. Brain Stimul 2013; 6 (2): 198-201.
[47]	Gersner R, Kravetz E, Feil J, Pell G, Zangen A. Long-term effects of repetitive transcranial magnetic stimulation on markers for neuroplasticity: Differential outcomes in anesthetized and awake animals. J Neurosci 2011; 31 (20): 7521-7526.
[48]	Lynch JH. Stellate ganglion block treats posttraumatic stress: An example of precision mental health. Brain Behav 2020; 10 (11): e01807.
[49]	Can AT, Hermens DF, Dutton M, et al. Low dose oral ketamine treatment in chronic suicidality: An open-label pilot study. Transl Psychiatry 2021; 11 (101).
[50]	Walkery A, Leader LD, Cooke E, VandenBerg A. Review of allopregnanolone agonist therapy for the treatment of depressive disorders. Drug Des Devel Ther 2021; 15: 3017-3026.
[51]	Gunduz-Bruce H, Silber C, Kaul I, et al. Trial of SAGE-217 in patients with major depressive disorder. N Engl J Med 2019; 381: 903–911.
[52]	Oldham MA, Ciraulo DA. Bright light therapy for depression: A review of its effects on chronobiology and the autonomic nervous system. Chronobiol Int 2014; 31 (3): 305-319.
[53]	Traffanstedt M, Mehta S, LoBello S. Major depression with seasonal variation. Is it a valid construct? Clinical Psychological Science 2016; 4 (5): 825–834.
[54]	Rosenthal, NE, Wehr, TA. (1987) Seasonal Affective Disorders. Psychiatric Annals. Vol. 17 (10): 670-674.
[55]	Golden RN, Gaynes BN, Ekstrom RD, et al. The efficacy of light therapy in the treatment of mood disorders: a review and meta-analysis of the evidence. Am J Psychiatry 2005; 162 (4): 656-662.
[56]	Terman M, Terman JS. Bright light therapy: side effects and benefits across the symptom spectrum. J Clin Psychiatry 1999; 60 (11): 799-808.
[57]	Young JW, Dulcis D. Investigating the mechanism (s) underlying switching between states in bipolar disorder. Eur J Pharmacol 2015; 759: 151-162.
[58]	Khedr EM, Elserogy Y, Fawzy M. Effect of psychotropic drugs on cortical excitability of patients with major depressive disorders: A transcranial magnetic stimulation study. Psychiatry Research 2020; 291: 113287.
[59]	El-Mallakh RS, Vöhringer PA, Ostacher MM, et al. Antidepressants worsen rapid-cycling course in bipolar depression: A STEP-BD randomized clinical trial. Journal of Affective Disorders 2015; 184: 318-321.
[60]	Goldberg JF, Truman CJ. Antidepressant-induced mania: an overview of current controversies. Bipolar Disorders 2001; 5 (6).
[61]	Yamaguchi Y, Kimoto S, Nagahama T, Kishimoto T. Dosage-related nature of escitalopram treatment-emergent mania/hypomania: a case series. Neuropsychiatr Dis Treat 2018; 14: 2099-2104.
[62]	Hett D, Marwaha S. Repetitive transcranial magnetic stimulation in the treatment of bipolar disorder. Ther Adv Psychopharmacol 2020; 18 (10).
[63]	Marzouk T, Winkelbeiner S, Azizi H, et al. Transcranial magnetic stimulation for positive symptoms in schizophrenia: A systematic review. Neuropsychobiology 2020; 79: 384–396.
[64]	Henkel AW, Welzel O, Groemer T W, et al. Fluoxetine prevents stimulation-dependent fatigue of synaptic vesicle exocytosis in hippocampal neurons. Journal of Neurochemistry 2010; 114 (3): 697-705.
[65]	Brody DJ, Gu Q. Antidepressant use among adults: United States, 2015-2018. National Center for Health Statistics. NCHS Data Brief No. 377, September 2020.
[66]	Sultan RS, Correll CU, Schoenbaum M, et al. National patterns of commonly prescribed psychotropic medications to young people. J Child Adolesc Psychopharmacol 2018; 28 (3): 158-165.
[67]	Chong Y, Fryer CD, Gu Q. Prescription sleep aid use among adults: United States, 2005-2010. NCHS Data Brief. 2013; (127): 1-8.
[68]	Cascade E, Kalali AH, Weisler RH. Varying uses of anticonvulsant medications. Psychiatry (Edgmont) 2008; 5 (6): 31-33.
[69]	Hirschfeld RM, Williams JB, Spitzer RL, et al. Development and validation of a screening instrument for bipolar spectrum disorder: the Mood Disorder Questionnaire. Am J Psychiatry 2000; 157 (11): 1873-1875.
[70]	Lubloy A, Kereszturi JL, Nemeth A, Mihalicza P. Exploring factors of diagnostic delay for patients with bipolar disorder: a population-based cohort study. BMC Psychiatry 2020; 20 (75).
[71]	Dagani J, Signorini G, Nielssen O, et al. Meta-analysis of the Interval between the onset and management of bipolar disorder. The Canadian Journal of Psychiatry 2016; 64 (4).
[72]	Grunze HCR. The effectiveness of anticonvulsants in psychiatric disorders. Dialogues Clin Neurosci 2008; 10 (1): 77-89.

Cite This Article

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2022). New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. American Journal of Clinical and Experimental Medicine, 10(1), 38-48. https://doi.org/10.11648/j.ajcem.20221001.15

Copy | Download

ACS Style

Michael Raymond Binder. New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. Am. J. Clin. Exp. Med. 2022, 10(1), 38-48. doi: 10.11648/j.ajcem.20221001.15

Copy | Download

AMA Style

Michael Raymond Binder. New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. Am J Clin Exp Med. 2022;10(1):38-48. doi: 10.11648/j.ajcem.20221001.15

Copy | Download

@article{10.11648/j.ajcem.20221001.15,
  author = {Michael Raymond Binder},
  title = {New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {1},
  pages = {38-48},
  doi = {10.11648/j.ajcem.20221001.15},
  url = {https://doi.org/10.11648/j.ajcem.20221001.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221001.15},
  abstract = {Although psychotherapy and pharmacotherapy continue to be first-line treatments for a wide range of mental and emotional disorders, a high percentage of patients are ultimately considered to be treatment-resistant. For more than half a century, electroconvulsive therapy had been the gold-standard for such patients. However, in recent years a variety of alternative treatment modalities have been developed for these patients, including deep brain stimulation, vagus nerve stimulation, repetitive transcranial magnetic stimulation, stellate ganglion block, and sub-anesthetic doses of the dissociative drug ketamine. Although these alternative treatments have offered new hope for many patients, there is a great deal of individual variability in their degree of effectiveness, and their mechanisms of action, like standard treatments, remain unclear. However, an emerging hypothesis contends that psychiatric symptoms are driven by pathological hyperactivity in symptom-related circuits in the brain. According to the Multi-Circuit Neuronal Hyperexcitability (MCNH) Hypothesis of Psychiatric Disorders, persistent firing in anxiety circuits causes persistent feelings of anxiety; persistent firing in depressive circuits causes persistent feelings of depression; persistent firing in cognitive circuits causes ruminative and obsessive thoughts; etc... The aim of this review is twofold: the first is to discuss the new hypothesis in relation to the aforementioned treatment strategies; and the second is to tease out the shared neurophysiological effects of past and present treatment strategies to determine whether they support or refute the new hypothesis. Clarifying the cause of mental illness is of critical importance to curbing the escalating mental health crisis, as new medications and emergent treatment strategies are failing to keep up with the steady rise in domestic disputes, suicides, homicides, and mass shootings that are driving the disintegration of individuals, families, and communities.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies
AU  - Michael Raymond Binder
Y1  - 2022/02/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221001.15
DO  - 10.11648/j.ajcem.20221001.15
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 38
EP  - 48
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221001.15
AB  - Although psychotherapy and pharmacotherapy continue to be first-line treatments for a wide range of mental and emotional disorders, a high percentage of patients are ultimately considered to be treatment-resistant. For more than half a century, electroconvulsive therapy had been the gold-standard for such patients. However, in recent years a variety of alternative treatment modalities have been developed for these patients, including deep brain stimulation, vagus nerve stimulation, repetitive transcranial magnetic stimulation, stellate ganglion block, and sub-anesthetic doses of the dissociative drug ketamine. Although these alternative treatments have offered new hope for many patients, there is a great deal of individual variability in their degree of effectiveness, and their mechanisms of action, like standard treatments, remain unclear. However, an emerging hypothesis contends that psychiatric symptoms are driven by pathological hyperactivity in symptom-related circuits in the brain. According to the Multi-Circuit Neuronal Hyperexcitability (MCNH) Hypothesis of Psychiatric Disorders, persistent firing in anxiety circuits causes persistent feelings of anxiety; persistent firing in depressive circuits causes persistent feelings of depression; persistent firing in cognitive circuits causes ruminative and obsessive thoughts; etc... The aim of this review is twofold: the first is to discuss the new hypothesis in relation to the aforementioned treatment strategies; and the second is to tease out the shared neurophysiological effects of past and present treatment strategies to determine whether they support or refute the new hypothesis. Clarifying the cause of mental illness is of critical importance to curbing the escalating mental health crisis, as new medications and emergent treatment strategies are failing to keep up with the steady rise in domestic disputes, suicides, homicides, and mass shootings that are driving the disintegration of individuals, families, and communities.
VL  - 10
IS  - 1
ER  -

Copy | Download

Author Information

Michael Raymond Binder

NorthShore University HealthSystem, Highland Park Hospital, Highland Park, USA

Download PDF

Sections

Plain Text BibTeX RIS

APA Style

Michael Raymond Binder. (2022). New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. American Journal of Clinical and Experimental Medicine, 10(1), 38-48. https://doi.org/10.11648/j.ajcem.20221001.15

Copy | Download

ACS Style

Michael Raymond Binder. New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. Am. J. Clin. Exp. Med. 2022, 10(1), 38-48. doi: 10.11648/j.ajcem.20221001.15

Copy | Download

AMA Style

Michael Raymond Binder. New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies. Am J Clin Exp Med. 2022;10(1):38-48. doi: 10.11648/j.ajcem.20221001.15

Copy | Download

@article{10.11648/j.ajcem.20221001.15,
  author = {Michael Raymond Binder},
  title = {New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies},
  journal = {American Journal of Clinical and Experimental Medicine},
  volume = {10},
  number = {1},
  pages = {38-48},
  doi = {10.11648/j.ajcem.20221001.15},
  url = {https://doi.org/10.11648/j.ajcem.20221001.15},
  eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ajcem.20221001.15},
  abstract = {Although psychotherapy and pharmacotherapy continue to be first-line treatments for a wide range of mental and emotional disorders, a high percentage of patients are ultimately considered to be treatment-resistant. For more than half a century, electroconvulsive therapy had been the gold-standard for such patients. However, in recent years a variety of alternative treatment modalities have been developed for these patients, including deep brain stimulation, vagus nerve stimulation, repetitive transcranial magnetic stimulation, stellate ganglion block, and sub-anesthetic doses of the dissociative drug ketamine. Although these alternative treatments have offered new hope for many patients, there is a great deal of individual variability in their degree of effectiveness, and their mechanisms of action, like standard treatments, remain unclear. However, an emerging hypothesis contends that psychiatric symptoms are driven by pathological hyperactivity in symptom-related circuits in the brain. According to the Multi-Circuit Neuronal Hyperexcitability (MCNH) Hypothesis of Psychiatric Disorders, persistent firing in anxiety circuits causes persistent feelings of anxiety; persistent firing in depressive circuits causes persistent feelings of depression; persistent firing in cognitive circuits causes ruminative and obsessive thoughts; etc... The aim of this review is twofold: the first is to discuss the new hypothesis in relation to the aforementioned treatment strategies; and the second is to tease out the shared neurophysiological effects of past and present treatment strategies to determine whether they support or refute the new hypothesis. Clarifying the cause of mental illness is of critical importance to curbing the escalating mental health crisis, as new medications and emergent treatment strategies are failing to keep up with the steady rise in domestic disputes, suicides, homicides, and mass shootings that are driving the disintegration of individuals, families, and communities.},
 year = {2022}
}

Copy | Download

TY  - JOUR
T1  - New Hypothesis on the Pathophysiology of Psychiatric Disorders Illuminates Shared Mechanism of Past and Emergent Treatment Strategies
AU  - Michael Raymond Binder
Y1  - 2022/02/28
PY  - 2022
N1  - https://doi.org/10.11648/j.ajcem.20221001.15
DO  - 10.11648/j.ajcem.20221001.15
T2  - American Journal of Clinical and Experimental Medicine
JF  - American Journal of Clinical and Experimental Medicine
JO  - American Journal of Clinical and Experimental Medicine
SP  - 38
EP  - 48
PB  - Science Publishing Group
SN  - 2330-8133
UR  - https://doi.org/10.11648/j.ajcem.20221001.15
AB  - Although psychotherapy and pharmacotherapy continue to be first-line treatments for a wide range of mental and emotional disorders, a high percentage of patients are ultimately considered to be treatment-resistant. For more than half a century, electroconvulsive therapy had been the gold-standard for such patients. However, in recent years a variety of alternative treatment modalities have been developed for these patients, including deep brain stimulation, vagus nerve stimulation, repetitive transcranial magnetic stimulation, stellate ganglion block, and sub-anesthetic doses of the dissociative drug ketamine. Although these alternative treatments have offered new hope for many patients, there is a great deal of individual variability in their degree of effectiveness, and their mechanisms of action, like standard treatments, remain unclear. However, an emerging hypothesis contends that psychiatric symptoms are driven by pathological hyperactivity in symptom-related circuits in the brain. According to the Multi-Circuit Neuronal Hyperexcitability (MCNH) Hypothesis of Psychiatric Disorders, persistent firing in anxiety circuits causes persistent feelings of anxiety; persistent firing in depressive circuits causes persistent feelings of depression; persistent firing in cognitive circuits causes ruminative and obsessive thoughts; etc... The aim of this review is twofold: the first is to discuss the new hypothesis in relation to the aforementioned treatment strategies; and the second is to tease out the shared neurophysiological effects of past and present treatment strategies to determine whether they support or refute the new hypothesis. Clarifying the cause of mental illness is of critical importance to curbing the escalating mental health crisis, as new medications and emergent treatment strategies are failing to keep up with the steady rise in domestic disputes, suicides, homicides, and mass shootings that are driving the disintegration of individuals, families, and communities.
VL  - 10
IS  - 1
ER  -

Copy | Download